Curium agreed to buy Lantheus in a deal valued up to $8 billion, pairing Curium’s global radiopharmaceutical manufacturing network and theranostics pipeline with Lantheus’ U.S. radiodiagnostics and cardiac franchise assets. Curium will pay $102.50 per Lantheus share in cash at closing, with potential milestone-based contingent value rights tied to sales. The combined company is expected to close in the first half of 2027, pending shareholder and regulatory approvals, and it plans to operate across the nuclear medicine supply chain—covering isotope production through imaging and targeted radionuclide therapy—across more than 70 countries.